研究人員>黃明熙 (Ming-Hsi Huang)

 
感染症與疫苗研究所
連絡電話:+886-37-206166 # 37742 (O) or 37749 (Lab)
傳真電話:+886-37-583009
E-mail:huangminghsi@nhri.edu.tw

 

Education

2001/10 – 2004/12     Ph.D., Faculty of Pharmacy, University of Montpellier 1, France

1997/09 – 1999/07     M.S., Institute of Biomedical Engineering, National Yang-Ming University, Taiwan

1993/09 – 1997/06     B.S., Department of Chemical Engineering, National Cheng-Kung University, Taiwan

 

Experience

2021/07 – present      Investigator, NIIDV, NHRI, Miaoli, Taiwan

2014/04 – 2021/06    Associate Investigator, NIIDV, NHRI, Miaoli, Taiwan

2009/08 – 2014/03    Assistant Investigator, NIIDV, NHRI, Miaoli, Taiwan

2005/07 – 2009/08    Postdoctoral Fellow, Vaccine R&D Center, NHRI, Miaoli, Taiwan

1999/09 – 2001/05    Military service

 

Honors & Awards

2021    IAAM Scientist Award in the Advanced Materials Lecture Series

2019    Young Scientist Award in National Health Research Institutes, Taiwan

2018    Futuristic Breakthrough Technology Award in Ministry of Science and Technology, Taiwan

1997    Research Creativity Award for undergraduate in National Science Council, Taiwan

 

Research Interests 

BEL Image Video: [Polysorbasome

Dr. Ming-Hsi Huang’s major research interest at NHRI has been focused on the development of novel delivery vehicles for generating vaccine-induced long-term immunity as well as immunoregulatory agents for manipulating effective/harmful immune responses. His research group was the pioneer who engineers amphiphilic bioresorbable polymers as emulsifiers to bring on novel biomimetic vesicles in the pursuit of innovative vaccine design. These studies were involved in the applications of micro/nano-encapsulation technology for a single-dose multivalent vaccine against emerging infectious diseases, in particular influenza-associated illness, hand-foot-mouth disease and coronavirus disease (COVID-19). During the past few years, he aimed to launch a mechanistic study on how colloidal vesicles interacting with immune cells and progressively elucidate the role of manufacturing process as well as each ingredient linking with vaccine immunogenicity. He also extends these aspects to optimize an appropriate vaccination route, such as subcutaneous, intramuscular or mucosal administration. These features are of great interest for further investigations on sustained delivery for cancer immunotherapy.

 

Research Activities & Accomplishment

In order to establish self-manufacturing capability for preparedness to any pandemic outbreak, National Institute of Infectious Diseases and Vaccinology (NIIDV) is currently developing cutting-edge technologies to rapidly produce sufficient quantities of vaccine supplies for massive vaccination. Among these, adjuvantation is a potential strategy to diminish antigen consumption by enhancing antigen-specific immunogenicity, i.e. antigen-sparing effect. However, traditional aluminum-based adjuvants (Alum), which are highly heterogeneous and difficult to manufacture in a consistent and reproducible manner, are obstacles in pandemic vaccine preparedness. Regarding this, it will be important to investigate the feasibility of enhancing vaccine immunogenicity with non-Alum-based adjuvants in vaccine formulations.

 

Immunobioengineering Laboratory (iBEL) of NIIDV is tasked with integrating immunobiology and engineering to facilitate the development of vaccine formulation and delivery for the induction of broadened and appropriate immune responses. Under the funding resources from NHRI and MOST, our research group has set up the platform technologies for vaccine formulation and delivery, including polymer synthesis, vaccine formulation, and immunological evaluation, as well as safety aspects and distribution of antigen and adjuvant in vivo. This platform offers several important advantages including antigen sparing, single injection, mucosal delivery, and cancer therapy.

 

Research frameworks. At the outset, we study on the engineering of amphiphilic bioresorbable polymers as a promising strategy for the delivery of vaccine antigens and/or immunostimulatory molecules; in parallel, we design and synthesize small antimicrobial peptide analogues. We also feature a mouse model for studying and understanding the properties of the candidate adjuvants interacting with immune cells as well as the roles in vaccine immunogenicity. In vivo distribution is investigated in mice to elucidate the targeting delivery of antigen-loaded systems. The histological examination of the tissue or organ integrities as well as the serum biochemistry test to study whether the novel compounds can turn on harmful reactions after injection in mice. Based on this platform, our research group has designed different vaccine formulations based on squalene emulsions as adjuvants for NIIDV candidate vaccines and investigated respective mode of action linking the physicochemical properties and the adjuvant activity. These experiences allowed us to foster the development of biotech companies in vaccine manufacturing and vaccine-related biotechnology.

Engineering amphiphilic bioresorbable polymers in the pursuit of innovative vaccine design. It has been well documented that the emulsions made by conventional emulsifiers such as sorbitan esters (Span®) or their ethoxylates (Tween®) may cause serious side effects, including severe non-immunological anaphylactoid reactions. Therefore, there is an unmet medical need to increase the number of well-defined emulsifiers in the preparation of emulsion-based vaccine adjuvants towards enhancing the vaccine efficacy without alternating the safety aspects. Toward this, a colloidal vesicle consisting of two immiscible liquids, metabolizable oil and aqueous solution, was stabilized by amphiphilic bioresorbable polymers consisting of hydrophilic groups and lipophilic groups. The hydrophilic group was made of poly(ethylene glycol) (PEG) or sorbitan; on the other hand, the lipophilic group comprised polyesters derived from lactyl (LA) and caproyl (CL) motifs, which have been widely regarded as degradable polyesters. These amphiphilic bioresorbable polymers act as surface-active agents to stabilize the oil/water interfaces and give rise to oil-shelled polysorbasomes (polymeric absorbable vesicles) during preparation and storage. The multiple phase character prolongs the retention of bioactive molecules. Following vaccination, the degradability intrinsic to bioresorbable polymers complies the vehicles’ being destroyed and further being absorbed in vivo. These features provide new insights into the field of sustained delivery based on bioresorbable amphiphilic engineering.

 

The merits of this invention are as follows:

  1. 安全Safe: All excipients used here showed main chain cleavage into small molecules and further absorbance in vivo, thereby conceptually conserving the vaccine safety.

  2. 柔軟Soft: Liquid–liquid colloidal vesicles are deformable and easily injected by a syringe with a small gauge needle, thereby potentially diminishing local reactions at the injection site. This feature encourages the use of such vesicles for massive vaccination.

  3. 細緻Small: Homogeneous colloidal particles can be controlled by passing them through an extruder membrane, and their size can therefore be controlled from 1,000 to 100 nm, thus facilitating the induction of appropriate immunity.

  4. 靈巧Smart: Oil-shelled capsules are useful for encapsulating and protecting designed bioactive molecules; the loss of the lipophilic moiety of amphiphiles directly affected the stability of the colloid after vaccination.

  5. 簡便Simple: The raw materials for colloids elaboration are commercially available and are largely used for vaccine/drug delivery; in addition, no complicating processes or supplemental equipment is required when performing the vaccine formulation, thus effectively reducing the cost.

  6. 善誘Stimulatory: Colloidal particles are immunogenic and facilitate the activation of immune cells, such that antigen-specific antibodies and cell-mediated immunity could be manipulated after the antigen being formulated with colloids.

 

Publications

國家衛生研究院機構典藏 (NHRI Institutional Repository): 黃明熙

Researcher ID: E-3872-2010

ORCID iD: 0000-0002-9670-3821

Comments are closed.